NEWARK, Calif., Nov. 20, 2018 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three upcoming investor conferences: the Piper Jaffray 30th Annual Healthcare Conference, the Evercore ISI HealthCONx Conference, and the BMO Prescriptions for Success Conference.
| Piper Jaffray 30th Annual Healthcare Conference | |
| Date: | Tuesday, November 27 |
| Time: | 12:00pm Eastern Time |
| Location: | Lotte New York Palace Hotel |
| Evercore ISI HealthCONx Conference | |
| Date: | Wednesday, November 28 |
| Time: | 9:05am Eastern Time |
| Location: | Boston Harbor Hotel |
| BMO Prescriptions for Success Conference | |
| Date: | Wednesday, December 12 |
| Time: | 11:40am Eastern Time |
| Location: | Mandarin Oriental NYC |
To access a live webcast and subsequent archived recording of each presentation, please visit the “Events” section on the CymaBay website at http://ir.cymabay.com/events.
About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist, currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with nonalcoholic steatohepatitis (NASH). Two Phase 2 studies of seladelpar established proof-of-concept in PBC. CymaBay is currently conducting a Phase 3 study of seladelpar for PBC and a Phase 2b study of seladelpar for NASH.
For additional information about CymaBay visit www.cymabay.com.
Contact:
Hans Vitzthum
LifeSci Advisors, LLC
617-535-7743
[email protected]
